Cargando…
Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab
The increasing use of immune checkpoint inhibitors, such as nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, for advanced neoplastic disease has revealed significant cutaneous immune-related adverse effects. Herein, we report a case of bullous pemphigoid (BP) secondary to nivolumab the...
Autores principales: | Olsen, Eric, Svoboda, Steven A, Saikaly, Sami K, Missall, Tricia A, Motaparthi, Kiran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491457/ https://www.ncbi.nlm.nih.gov/pubmed/37692698 http://dx.doi.org/10.7759/cureus.43230 |
Ejemplares similares
-
A Case of Bullous Pemphigoid: A Prevalent and Potentially Fatal Condition
por: Parellada, Jorge, et al.
Publicado: (2018) -
A Case of Bullous Pemphigoid Associated With Nivolumab Therapy
por: Gotera, Nico, et al.
Publicado: (2022) -
When Bullous Pemphigoid Is Not Bullous Pemphigoid: The Importance of Going Beyond Direct Immunofluorescence
por: Hopkins, Christina R, et al.
Publicado: (2022) -
Combination Therapy of Plasma Exchange and Rituximab to Treat Cicatricial Pemphigoid and Bullous Pemphigoid
por: Kunadia, Anuj, et al.
Publicado: (2021) -
Diffuse blistering rash with ocular involvement
por: Margulies, Shae, et al.
Publicado: (2022)